NanJing Pharmaceutical Co Ltd
Nanjing Pharmaceutical Group Company Limited engages in the drug distribution businesses in China. It also involved in the wholesale and retail of medical device distribution; pharmaceutical logistics; and internet drug retail business. The company was formerly known as NanJing Pharmaceutical Company Limited and change its name to Nanjing Pharmaceutical Group Company Limited in December 2025. Nan… Read more
NanJing Pharmaceutical Co Ltd (600713) - Net Assets
Latest net assets as of September 2025: CN¥7.95 Billion CNY
Based on the latest financial reports, NanJing Pharmaceutical Co Ltd (600713) has net assets worth CN¥7.95 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥34.05 Billion) and total liabilities (CN¥26.09 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥7.95 Billion |
| % of Total Assets | 23.36% |
| Annual Growth Rate | 16.15% |
| 5-Year Change | 61.57% |
| 10-Year Change | 189.88% |
| Growth Volatility | 34.46 |
NanJing Pharmaceutical Co Ltd - Net Assets Trend (1994–2024)
This chart illustrates how NanJing Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NanJing Pharmaceutical Co Ltd (1994–2024)
The table below shows the annual net assets of NanJing Pharmaceutical Co Ltd from 1994 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥7.79 Billion | +7.35% |
| 2023-12-31 | CN¥7.25 Billion | +8.37% |
| 2022-12-31 | CN¥6.69 Billion | +27.92% |
| 2021-12-31 | CN¥5.23 Billion | +8.58% |
| 2020-12-31 | CN¥4.82 Billion | +6.64% |
| 2019-12-31 | CN¥4.52 Billion | +10.00% |
| 2018-12-31 | CN¥4.11 Billion | +28.95% |
| 2017-12-31 | CN¥3.19 Billion | +3.82% |
| 2016-12-31 | CN¥3.07 Billion | +14.25% |
| 2015-12-31 | CN¥2.69 Billion | +10.23% |
| 2014-12-31 | CN¥2.44 Billion | +89.23% |
| 2013-12-31 | CN¥1.29 Billion | -1.95% |
| 2012-12-31 | CN¥1.31 Billion | -3.27% |
| 2011-12-31 | CN¥1.36 Billion | +7.45% |
| 2010-12-31 | CN¥1.26 Billion | +69.70% |
| 2009-12-31 | CN¥744.78 Million | +21.96% |
| 2008-12-31 | CN¥610.69 Million | -12.87% |
| 2007-12-31 | CN¥700.93 Million | +8.84% |
| 2006-12-31 | CN¥643.97 Million | -0.46% |
| 2005-12-31 | CN¥646.94 Million | +5.34% |
| 2004-12-31 | CN¥614.14 Million | +0.38% |
| 2003-12-31 | CN¥611.84 Million | +21.09% |
| 2002-12-31 | CN¥505.29 Million | +7.04% |
| 2001-12-31 | CN¥472.04 Million | -3.06% |
| 2000-12-31 | CN¥486.93 Million | +9.52% |
| 1999-12-31 | CN¥444.61 Million | +4.14% |
| 1998-12-31 | CN¥426.92 Million | +70.13% |
| 1997-12-31 | CN¥250.94 Million | +17.90% |
| 1996-12-31 | CN¥212.84 Million | +159.52% |
| 1995-12-31 | CN¥82.01 Million | -5.91% |
| 1994-12-31 | CN¥87.17 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NanJing Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 18997.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.65 Billion | 38.76% |
| Common Stock | CN¥1.31 Billion | 19.15% |
| Other Components | CN¥2.88 Billion | 42.09% |
| Total Equity | CN¥6.84 Billion | 100.00% |
NanJing Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of NanJing Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NS UTD KAIUN KAISHA LTD.
F:8WN
|
$407.96 Million |
|
Guardian Capital Group Limited
PINK:GRCGF
|
$408.08 Million |
|
Scandi Standard publ AB
ST:SCST
|
$408.14 Million |
|
TechnoPro Holdings Inc
PINK:TCCPY
|
$408.17 Million |
|
RLH Properties S.A.B. de C.V
MX:RLHA
|
$407.92 Million |
|
Raydium Semi-Conductor
TW:3592
|
$407.88 Million |
|
TSE Co. Ltd
KQ:131290
|
$407.87 Million |
|
Kaleseramik Canakkale Kalebodur Seramik Sanayi A.S.
IS:KLSER
|
$407.62 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NanJing Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,435,194,000 to 6,838,027,000, a change of 402,833,000 (6.3%).
- Net income of 570,628,000 contributed positively to equity growth.
- Dividend payments of 504,825,000 reduced retained earnings.
- Share repurchases of 2,117,074 reduced equity.
- Other factors increased equity by 339,147,074.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥570.63 Million | +8.34% |
| Dividends Paid | CN¥504.82 Million | -7.38% |
| Share Repurchases | CN¥2.12 Million | -0.03% |
| Other Changes | CN¥339.15 Million | +4.96% |
| Total Change | CN¥- | 6.26% |
Book Value vs Market Value Analysis
This analysis compares NanJing Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.03x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 25.42x to 1.03x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1994-12-31 | CN¥0.21 | CN¥5.43 | x |
| 1995-12-31 | CN¥0.20 | CN¥5.43 | x |
| 1996-12-31 | CN¥0.52 | CN¥5.43 | x |
| 1997-12-31 | CN¥0.62 | CN¥5.43 | x |
| 1998-12-31 | CN¥0.98 | CN¥5.43 | x |
| 1999-12-31 | CN¥1.07 | CN¥5.43 | x |
| 2000-12-31 | CN¥1.12 | CN¥5.43 | x |
| 2001-12-31 | CN¥1.06 | CN¥5.43 | x |
| 2002-12-31 | CN¥1.07 | CN¥5.43 | x |
| 2003-12-31 | CN¥1.14 | CN¥5.43 | x |
| 2004-12-31 | CN¥1.11 | CN¥5.43 | x |
| 2005-12-31 | CN¥1.15 | CN¥5.43 | x |
| 2006-12-31 | CN¥0.77 | CN¥5.43 | x |
| 2007-12-31 | CN¥0.84 | CN¥5.43 | x |
| 2008-12-31 | CN¥0.96 | CN¥5.43 | x |
| 2009-12-31 | CN¥0.93 | CN¥5.43 | x |
| 2010-12-31 | CN¥1.50 | CN¥5.43 | x |
| 2011-12-31 | CN¥1.35 | CN¥5.43 | x |
| 2012-12-31 | CN¥1.48 | CN¥5.43 | x |
| 2013-12-31 | CN¥1.52 | CN¥5.43 | x |
| 2014-12-31 | CN¥3.02 | CN¥5.43 | x |
| 2015-12-31 | CN¥2.57 | CN¥5.43 | x |
| 2016-12-31 | CN¥2.93 | CN¥5.43 | x |
| 2017-12-31 | CN¥3.10 | CN¥5.43 | x |
| 2018-12-31 | CN¥3.61 | CN¥5.43 | x |
| 2019-12-31 | CN¥3.85 | CN¥5.43 | x |
| 2020-12-31 | CN¥4.09 | CN¥5.43 | x |
| 2021-12-31 | CN¥4.42 | CN¥5.43 | x |
| 2022-12-31 | CN¥4.78 | CN¥5.43 | x |
| 2023-12-31 | CN¥4.98 | CN¥5.43 | x |
| 2024-12-31 | CN¥5.25 | CN¥5.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NanJing Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.34%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.06%
- • Asset Turnover: 1.75x
- • Equity Multiplier: 4.49x
- Recent ROE (8.34%) is above the historical average (7.47%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1994 | 15.68% | 3.37% | 1.54x | 3.02x | CN¥4.95 Million |
| 1995 | 21.04% | 3.52% | 1.80x | 3.32x | CN¥9.06 Million |
| 1996 | 14.20% | 6.01% | 1.16x | 2.04x | CN¥8.94 Million |
| 1997 | 15.19% | 6.54% | 1.26x | 1.84x | CN¥13.01 Million |
| 1998 | 13.43% | 6.10% | 1.01x | 2.17x | CN¥13.70 Million |
| 1999 | 17.03% | 6.46% | 1.21x | 2.18x | CN¥30.55 Million |
| 2000 | 8.65% | 2.97% | 1.08x | 2.69x | CN¥-6.18 Million |
| 2001 | 7.77% | 2.36% | 1.22x | 2.69x | CN¥-9.68 Million |
| 2002 | 6.45% | 1.36% | 1.14x | 4.16x | CN¥-15.49 Million |
| 2003 | 4.41% | 0.49% | 1.60x | 5.65x | CN¥-25.98 Million |
| 2004 | 0.53% | 0.05% | 1.68x | 6.92x | CN¥-42.88 Million |
| 2005 | 3.91% | 0.29% | 1.87x | 7.09x | CN¥-28.57 Million |
| 2006 | 2.34% | 0.16% | 1.85x | 7.93x | CN¥-35.61 Million |
| 2007 | 9.25% | 0.50% | 1.87x | 9.91x | CN¥-3.78 Million |
| 2008 | 6.27% | 0.27% | 2.26x | 10.42x | CN¥-18.05 Million |
| 2009 | 8.33% | 0.33% | 2.15x | 11.74x | CN¥-9.29 Million |
| 2010 | 0.93% | 0.06% | 1.83x | 8.35x | CN¥-90.92 Million |
| 2011 | -19.44% | -1.06% | 1.90x | 9.61x | CN¥-276.55 Million |
| 2012 | 1.08% | 0.06% | 1.95x | 9.24x | CN¥-89.09 Million |
| 2013 | 3.67% | 0.21% | 1.94x | 9.17x | CN¥-66.60 Million |
| 2014 | 6.02% | 0.58% | 1.94x | 5.31x | CN¥-85.24 Million |
| 2015 | 6.81% | 0.63% | 1.97x | 5.47x | CN¥-73.39 Million |
| 2016 | 6.86% | 0.67% | 1.91x | 5.32x | CN¥-82.35 Million |
| 2017 | 8.37% | 0.85% | 1.73x | 5.73x | CN¥-45.33 Million |
| 2018 | 7.20% | 0.84% | 1.60x | 5.33x | CN¥-102.62 Million |
| 2019 | 8.64% | 0.93% | 1.69x | 5.47x | CN¥-54.44 Million |
| 2020 | 8.84% | 0.95% | 1.70x | 5.50x | CN¥-49.34 Million |
| 2021 | 10.97% | 1.12% | 1.74x | 5.62x | CN¥44.55 Million |
| 2022 | 9.93% | 1.19% | 1.59x | 5.28x | CN¥-4.32 Million |
| 2023 | 8.98% | 1.08% | 1.89x | 4.41x | CN¥-65.69 Million |
| 2024 | 8.34% | 1.06% | 1.75x | 4.49x | CN¥-113.17 Million |
Industry Comparison
This section compares NanJing Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $793,872,624
- Average return on equity (ROE) among peers: 7.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NanJing Pharmaceutical Co Ltd (600713) | CN¥7.95 Billion | 15.68% | 3.28x | $407.93 Million |
| Zhejiang Int'L Group Co Ltd (000411) | $189.44 Million | 3.08% | 4.33x | $199.04 Million |
| Zhejiang Zhenyuan Share Co Ltd (000705) | $485.74 Million | 1.60% | 0.77x | $307.06 Million |
| Hunan Jingfeng Pharmaceutical (000908) | $336.40 Million | 0.81% | 1.44x | $202.85 Million |
| Hubei Guangji Pharmaceutical Co Ltd (000952) | $1.49 Billion | 3.37% | 0.66x | $229.65 Million |
| Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) | $1.25 Billion | 8.38% | 0.07x | $144.69 Million |
| Yifan Xinfu Pharmaceutical Co Ltd (002019) | $507.64 Million | 23.17% | 1.09x | $1.01 Billion |
| Guangdong Jiaying Pharmaceutical Co Ltd (002198) | $226.35 Million | 6.06% | 0.04x | $447.60 Million |
| Chongqing Lummy Pharmaceutical (300006) | $1.88 Billion | -4.66% | 0.52x | $475.43 Million |
| Zhejiang Jolly Pharmaceutical Co Ltd (300181) | $1.39 Billion | 1.50% | 0.52x | $1.19 Billion |
| Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) | $181.38 Million | 29.65% | 0.05x | $893.83 Million |